Marex Group’s Teva Pharmaceuticals TEVA Stock Holding History

Marex Group’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$505K	Sell	14,900 -7,629	-34%	-$254K	﹤0.01%	696
2026 Q1	$679K	Sell	22,529 -3,518	-14%	-$113K	﹤0.01%	536
2025 Q4	$813K	Sell	26,047 -5,306	-17%	-$131K	0.01%	443
2025 Q3	$633K	Buy	31,353 +3,698	+13%	+$65K	﹤0.01%	440
2025 Q2	$463K	Buy	27,655 +4,155	+18%	+$67K	﹤0.01%	384
2025 Q1	$361K	Buy	+23,500	New	+$420K	0.01%	416
2023 Q3	–	Sell	-269,686	Closed	-$2.03M	–	259
2023 Q2	$2.03M	Buy	269,686 +153,561	+132%	+$1.25M	0.37%	56
2023 Q1	$1.03M	Buy	+116,125	New	+$1.15M	0.14%	104

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Marex Group's TEVA Position: Q2 2026 in Review

Marex Group reduced its Teva Pharmaceuticals (TEVA) stake by 34% in Q2 2026, selling an estimated $254K and leaving 14,900 shares worth $505K. The position accounts for ﹤0.01% of the portfolio, ranked #696.

Marex Group first reported a position in TEVA in Q1 2023 and has held it in 8 quarters since. The position peaked at $2.03M in Q2 2023. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Marex Group held 14,900 shares of Teva Pharmaceuticals worth $505K as of Q2 2026.
Marex Group sold 7,629 Teva Pharmaceuticals shares in Q2 2026, an estimated $254K.
Teva Pharmaceuticals made up ﹤0.01% of Marex Group's portfolio in Q2 2026, its #696 holding.
Marex Group first reported a position in Teva Pharmaceuticals in Q1 2023 and has held it in 8 quarters since.
Marex Group's Teva Pharmaceuticals position peaked at $2.03M in Q2 2023.
673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Marex Group's 13F filing for Q2 2026, filed 14 Aug 2026.